Scarica l'app Stockscreener
93.69
1.23%
-1.17
Pre-mercato:
97.46
3.77
+4.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte Corporation (INCY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Incyte Drug Shows Reduced COPD-like HS Flares in Phase III Data - MyChesCo
Hidradenitis Suppurativa Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | InflaRx, Novartis, UCB, AbbVie, Pfizer, Amgen, Incyte Corp, CSL - barchart.com
Incyte Names Cagnoni President, Announces Leadership Changes - MyChesCo
Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch
Allspring Global Investments Holdings LLC Buys 112,736 Shares of Incyte Corporation $INCY - MarketBeat
Toth Financial Advisory Corp Acquires Shares of 12,280 Incyte Corporation $INCY - MarketBeat
Non Muscle Invasive Bladder Cancer Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Incyte Corp - barchart.com
Non Muscle Invasive Bladder Cancer Pipeline 2026: Key - openPR.com
Incyte reports strong 54-week data from late-stage skin disorder study - MSN
Adagene reveals Incyte deal, data update and public offering - The Pharma Letter
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte Corp (INCY) board rep logs 421-share RSU fee grant - Stock Titan
Incyte (INCY) director Edmund Harrigan takes 269-share grant in fees - Stock Titan
Incyte (INCY) director takes 265-share board fee in stock - Stock Titan
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) - finance.yahoo.com
Citizens reiterates Incyte stock rating on pipeline progress By Investing.com - ca.investing.com
Citizens reiterates Incyte stock rating on pipeline progress - Investing.com
J. Safra Sarasin Holding AG Decreases Stake in Incyte Corporation $INCY - MarketBeat
Barclays Maintains Overweight on Incyte (INCY) Mar 2026 - Meyka
Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects - MSN
INCY Technical Analysis | Trend, Signals & Chart Patterns | INCYTE CORP (NASDAQ:INCY) - ChartMill
Incyte Corporation (INCY) Announces Board Member Resignation - GuruFocus
Incyte board member Susanne Schaffert to step down in April By Investing.com - Investing.com India
Incyte board member Susanne Schaffert to step down in April - Investing.com
Incyte's Susanne Schaffert to Resign from Board Effective April 15, 2026 - TradingView
Incyte (INCY) Board member Susanne Schaffert to step down April 15, 2026 - Stock Titan
INCY: HC Wainwright & Co. Reiterates 'Buy' Rating and $135 Price Target | INCY Stock News - GuruFocus
Incyte Shares Positive 54-Week Results From Advanced Skin Condition Trial - Bitget
Incyte Reports Strong 54-Week Data From Late-Stage Skin Disorder Study - finance.yahoo.com
William Blair reiterates Market Perform on Incyte stock after HS data - Investing.com Canada
MoonLake and Incyte progress HS prospects at AAD - The Pharma Letter
Stifel reiterates Incyte stock rating on hidradenitis drug data By Investing.com - Investing.com India
Stifel reiterates Incyte stock rating on hidradenitis drug data - Investing.com
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack - Yahoo Finance
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting - BioSpace
(INCY.O) | Stock Price & Latest News - Reuters
Incyte Corporation $INCY Shares Purchased by SG Americas Securities LLC - MarketBeat
Fairvoy Private Wealth Boosts Incyte Corporation Holdings - National Today
Vanguard disaggregates holdings; reports 0% in Incyte (INCY) - Stock Titan
Incyte Corporation (INCY) Announces Executive Leadership Title C - GuruFocus
Incyte Announces Key Executive Leadership Changes and Integration of U.S. Commercial Teams for Long-Term Growth - minichart.com.sg
INCYTE (NASDAQ: INCY) EVP sees 537 shares withheld to cover RSU taxes - Stock Titan
Pablo J. Cagnoni named President at Incyte; William J. Meury remains CEO - TradingView
Incyte (NASDAQ: INCY) appoints new President and consolidates U.S. commercial - Stock Titan
UBS Lowers Price Target for Incyte (INCY) While Maintaining Neut - GuruFocus
0.47%
2.75%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):